Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia

Abstract Aims/Introduction To investigate the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus, with a focus on hypoglycemia. Materials and Methods Type 2 diabetes mellitus patients who started sitagliptin therapy and were followed for 52 weeks were enrolled in th...

Full description

Bibliographic Details
Main Authors: Masahiro Fukuda, Kunihiro Doi, Masahiro Sugawara, Koichi Mochizuki
Format: Article
Language:English
Published: Wiley 2019-03-01
Series:Journal of Diabetes Investigation
Subjects:
Online Access:https://doi.org/10.1111/jdi.12915
_version_ 1818574852422893568
author Masahiro Fukuda
Kunihiro Doi
Masahiro Sugawara
Koichi Mochizuki
author_facet Masahiro Fukuda
Kunihiro Doi
Masahiro Sugawara
Koichi Mochizuki
author_sort Masahiro Fukuda
collection DOAJ
description Abstract Aims/Introduction To investigate the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus, with a focus on hypoglycemia. Materials and Methods Type 2 diabetes mellitus patients who started sitagliptin therapy and were followed for 52 weeks were enrolled in the Impact of Sitagliptin on Diabetes Mellitus in Japanese Elderly Patients study. The frequency of hypoglycemia and knowledge of hypoglycemia were analyzed using a questionnaire. Results In total, 5,130 patients (aged 73.8 ± 6.1 years) were analyzed. A significant reduction in glycated hemoglobin (−0.7 ± 1.1%, P < 0.001) and glycoalbumin levels (−2.2 ± 3.8%, P < 0.001) was observed at week 52. The percentage of patients with hypoglycemia did not increase from the baseline (3.3%) to week 52 (2.8%) of sitagliptin administration. Hypoglycemia incidence was significantly higher for combination therapy with insulin (odds ratio 17.75, P < 0.001) or sulfonylurea (odds ratio 2.22, P < 0.001). The increase in sitagliptin dose for combination therapy with antidiabetic drug(s) increased the percentage of patients with hypoglycemia (5.6% in sitagliptin increased subgroup, 2.4% in sitagliptin maintained subgroup, P < 0.01). The awareness of hypoglycemia symptoms and attitude to carry glucose as a countermeasure to prevent hypoglycemia increased during the study. Conclusions Sitagliptin did not increase the percentage of patients with hypoglycemia among elderly patients with type 2 diabetes mellitus. However, hypoglycemia occurred more frequently in add‐on therapy to sulfonylurea or when the sitagliptin dose was increased in combination therapy, showing that sitagliptin should be used with caution.
first_indexed 2024-12-15T00:31:36Z
format Article
id doaj.art-cfb2385f59b94279bf2f0a8217d3715f
institution Directory Open Access Journal
issn 2040-1116
2040-1124
language English
last_indexed 2024-12-15T00:31:36Z
publishDate 2019-03-01
publisher Wiley
record_format Article
series Journal of Diabetes Investigation
spelling doaj.art-cfb2385f59b94279bf2f0a8217d3715f2022-12-21T22:42:00ZengWileyJournal of Diabetes Investigation2040-11162040-11242019-03-0110238339110.1111/jdi.12915Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemiaMasahiro Fukuda0Kunihiro Doi1Masahiro Sugawara2Koichi Mochizuki3Fukuda Clinic OsakaJapanDoi Clinic KyotoJapanSugawara Clinic Tokyo JapanMochizuki Naika Clinic Tokyo JapanAbstract Aims/Introduction To investigate the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus, with a focus on hypoglycemia. Materials and Methods Type 2 diabetes mellitus patients who started sitagliptin therapy and were followed for 52 weeks were enrolled in the Impact of Sitagliptin on Diabetes Mellitus in Japanese Elderly Patients study. The frequency of hypoglycemia and knowledge of hypoglycemia were analyzed using a questionnaire. Results In total, 5,130 patients (aged 73.8 ± 6.1 years) were analyzed. A significant reduction in glycated hemoglobin (−0.7 ± 1.1%, P < 0.001) and glycoalbumin levels (−2.2 ± 3.8%, P < 0.001) was observed at week 52. The percentage of patients with hypoglycemia did not increase from the baseline (3.3%) to week 52 (2.8%) of sitagliptin administration. Hypoglycemia incidence was significantly higher for combination therapy with insulin (odds ratio 17.75, P < 0.001) or sulfonylurea (odds ratio 2.22, P < 0.001). The increase in sitagliptin dose for combination therapy with antidiabetic drug(s) increased the percentage of patients with hypoglycemia (5.6% in sitagliptin increased subgroup, 2.4% in sitagliptin maintained subgroup, P < 0.01). The awareness of hypoglycemia symptoms and attitude to carry glucose as a countermeasure to prevent hypoglycemia increased during the study. Conclusions Sitagliptin did not increase the percentage of patients with hypoglycemia among elderly patients with type 2 diabetes mellitus. However, hypoglycemia occurred more frequently in add‐on therapy to sulfonylurea or when the sitagliptin dose was increased in combination therapy, showing that sitagliptin should be used with caution.https://doi.org/10.1111/jdi.12915HypoglycemiaSitagliptinSulfonylurea
spellingShingle Masahiro Fukuda
Kunihiro Doi
Masahiro Sugawara
Koichi Mochizuki
Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
Journal of Diabetes Investigation
Hypoglycemia
Sitagliptin
Sulfonylurea
title Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
title_full Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
title_fullStr Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
title_full_unstemmed Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
title_short Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
title_sort efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus a focus on hypoglycemia
topic Hypoglycemia
Sitagliptin
Sulfonylurea
url https://doi.org/10.1111/jdi.12915
work_keys_str_mv AT masahirofukuda efficacyandsafetyofsitagliptininelderlypatientswithtype2diabetesmellitusafocusonhypoglycemia
AT kunihirodoi efficacyandsafetyofsitagliptininelderlypatientswithtype2diabetesmellitusafocusonhypoglycemia
AT masahirosugawara efficacyandsafetyofsitagliptininelderlypatientswithtype2diabetesmellitusafocusonhypoglycemia
AT koichimochizuki efficacyandsafetyofsitagliptininelderlypatientswithtype2diabetesmellitusafocusonhypoglycemia